Pelareorep in Gastrointestinal Cancers
For the growing number of patients with gastrointestinal cancers cancers, effective therapies that improve treatment outcomes and meaningfully extend survival are limited.1 Indeed, fewer than 12% of patients receiving the current standard-of-care for pancreatic cancer survive 5 years beyond their diagnosis.2 To address this profoundly unmet need, Oncolytics is conducting the GOBLET trial to examine the potential of pelareorep and the checkpoint inhibitor atezolizumab in addition to standard-of-care therapy, where appropriate, for gastrointestinal cancers, including advanced/metastatic pancreatic cancer. The combination of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab received FDA Fast Track designation for the treatment of advanced/metastatic pancreatic cancer. As a result of the Fast Track designation and the promising data reported to date, Oncolytics is planning an adaptive Phase 3 program and intends to manage it directly within its Clinical Group and a contract research organization (CRO) with the goal of enrolling the first patient in mid-2024.
Hakuno SK, Michiels E, Kuhlemaijer EB, Rooman I, Hawinkels LJAC, Slingerland M. Multicellular Modelling of Difficult-to-Treat Gastrointestinal Cancers: Current Possibilities and Challenges. Int J Mol Sci. 2022 Mar 15;23(6):3147. doi: 10.3390/ijms23063147. PMID: 35328567; PMCID: PMC8955095.
National Cancer Institute. (2021). Cancer Stat Facts: Pancreatic Cancer. SEER Program, Surveillance, Epidemiology, and End Results. Retrieved April 5, 2023, from https://seer.cancer.gov/statfacts/html/pancreas.html
Learn more about how pelareorep remodels tumor microenvironments to enable immune access while training the immune system to recognize and kill tumor cells in patients with pancreatic and other GI cancers.
For the latest updates on the GOBLET trial, click the link below.
For questions regarding our science, partnership opportunities, or other inquiries, we encourage you to reach out.